Qure (NASDAQ:QURE – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with ...

Qure (NASDAQ:QURE – Get Free Report) shares were up 5.8% during mid-day trading on Friday after Mizuho raised their price ...

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the ...

Y Intercept Hong Kong Ltd bought a new position in shares of uniQure (NASDAQ:QURE – Free Report) during the 3rd quarter, ...

Last year's first quarter saw a flurry of biotech takeover deals, starting off with Johnson & Johnson (JNJ)/Ambrx, Merck (MRK)/Harpoon, GSK (GSK)/Aiolos and Novartis(NVS)/Calypso in early January.

UniQure (NASDAQ:QURE) stock shot up 90% Tuesday morning on news that the company had reached an agreement with the FDA on key elements for an accelerated approval pathway for its drug AMT-130 in t ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks uniQure ( (QURE)) has provided an update. uniQure has reached an agreement with the FDA on critical elements for ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may ...

During the first 12 days of December, shares of uniQure rocketed 152% higher, and investors want to know if this stock has legs that can propel it further in 2025. Let's weigh the positive news that ...